Azra Takhvar - Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Somaye Akbari - Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Effat Souri - Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Reza Ahmadkhaniha - Department of Human Ecology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Ali Morsali - Department of Chemistry, Faculty of Sciences, Tarbiat Modares University, Tehran, Iran
Mohammad Reza Khoshayand - Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medial Sciences.
Mohsen Amini - Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

In this research, a reversed phase high performance liquid chromatographic method was developed for the simultaneous determination of two tyrosine kinase inhibitors, nilotinib and sorafenib. Separation was performed on an Agilent C۱۸ column (۴.۶×۲۵۰ mm, ۵µm) with mobile phase composition of potassium dihydrogen phosphate buffer (۲۵ mM, pH ۴.۲) and acetonitrile (۳۵:۶۵ v/v) at ۱.۲ mL/min with UV detection at ۲۶۵ nm. Specificity, linearity, precision, accuracy, and robustness of the proposed method were all assessed. Nilotinib and sorafenib had estimated retention times of ۵.۱ and ۵.۹ minutes, respectively. Linear concentration ranges for nilotinib and sorafenib, were determined as ۰.۰۵-۱ µg/mL and ۱۰-۴۵ µg/mL with comparable coefficient correlations (۰.۹۹۹). For nilotinib and sorafenib, the limits of detection (LOD) were determined as ۰.۰۳۰ and ۰.۰۲۰ µg/mL, while the limits of quantification (LOQ) were ۰.۱۰۱ and ۰.۰۶۹ µg/mL respectively.

HPLC, Nilotinib, sorafenib, Determination, tyrosine kinase inhibitor